1. Multiplicity adjustment in seamless phase II/III adaptive trials using biomarkers for dose selection;Li,2015
2. Oncology Center of Excellence (OCE) Project Optimus: Reforming the dose optimization and dose selection paradigm in oncology;U.S. Food and Drug Administration,2023
3. Optimizing Dosing in Oncology Drug Development;Blumenthal,2021
4. An adaptive seamless phase 2-3 design with multiple endpoints;Jin;Stat. Methods Med. Res.,2021
5. A seamless adaptive 2-in-1 design expanding a phase 2 trial for treatment or dose selection into a phase 3 trial;Jin;Stat. Biopharm. Res.,2021